Skip to content

Study on the Application of Low-Sodium Formula Salt in Hypertensive Patients with Diabetes

Study on the Application of Low-Sodium Formula Salt in Hypertensive Patients with Diabetes

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000029017
Enrollment
Unknown
Registered
2020-01-11
Start date
2020-02-18
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension, Type 2 diabetes

Interventions

Common salt group:DASH diet and common salt
65% low sodium salt group:DASH diet and 65% low sodium salt
18% low sodium salt group:DASH diet and 18% low sodium salt

Sponsors

Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Diabetes combined with hypertension, currently taking medications to lower blood sugar and blood pressure (the type and dose remain unchanged for > 3 months). Baseline untreated systolic blood pressure is between 130-159mmHg, and baseline diastolic blood pressure is 80-100mmHg; 2. Age 35-75 years; 3. The place of residence is near the hospital. There is no plan to transfer out or go out from March to June 2020. You can come to the hospital for follow-up every week; 4. Able to strictly follow the daily lunch and dinner we provide during the test; 5. Subjects and their families living in common agreed to conduct the study and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Malignant tumor, acute myocardial infarction and acute stroke within three months or expected survival time is less than one year; 2. Have secondary hypertension such as hypercortisolism or hyperaldosteronism; 3. Acute diseases such as upper respiratory infection, fever, severe diarrhea, etc.; 4. Deafness, dementia and other disabilities, as well as severe depression or other mental disorders; 5. Taking low sodium salt or participating in other clinical research; 6. Abnormal liver function, alanine aminotransferase or aspartate aminotransferase is more than 2 times the upper limit of normal value, or total bilirubin is larger than the upper limit of normal value; 7. Renal dysfunction, patients with stage 4 and 5 chronic kidney disease; 8. Abnormal serum potassium, less than 3.5mmol / L or more than 5.5mmol / L; 9. Taking potassium diuretics; 10. Pregnant women, or those with other serious chronic diseases, and others who should take the test product; 11. Disability cannot follow up on time.

Design outcomes

Primary

MeasureTime frame
blood pressure;fasting blood sugar;2-hour postprandial blood glucose;

Countries

China

Contacts

Public ContactLihong Mu

Chongqing Medical University

1097123703@qq.com+86 13608360737

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 8, 2026